Epilepsy Clinical Trials in New York

Showing 61-80 of 127 trials

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

NCT02091375

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.

EpilepsyDravet Syndrome

Jazz Pharmaceuticals120 participantsStarted Mar 2015

Miami, Florida, United States • Orlando, Florida, United States • Atlanta, Georgia, United States +19 more locations

COMPLETEDPhase 4< 1 mile

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129

This study will assess the retention rate of perampanel when given as monotherapy or first adjunctive therapy in participants with partial-onset seizures or primary generalized tonic clonic seizures. The study consists of 4 periods: a Screening Period (to start no earlier than 6 weeks before the first dose of study drug), a Titration Period (up to 13 weeks), a Maintenance Period (39 weeks), and a Follow-Up Period (4 weeks).

Partial Onset SeizuresSecondarily Generalized SeizuresPrimary Generalized Tonic-Clonic Seizures

Eisai Inc.54 participantsStarted Aug 2017

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +21 more locations

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Epilepsy Trials in Other Cities

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Staccato Alprazolam and Photoparoxysmal Response

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

Neuroimaging Biomarker for Seizures

Does Use of Rapid Response EEG Impact Clinical Decision Making

Diffusion MRI-1 Imaging Database

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy

A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

Other Conditions in New York